NPPA Slashes Prices of 543 Oncology Drugs by Up to 93% Effective Nov 9

In a landmark policy intervention aimed at easing the financial burden on oncology patients and their families, the National Pharmaceutical Pricing Authority (NPPA) has published a revised price schedule covering 543 cancer drug brands and formulation packs. Issued on the basis of updated pricing data submitted by pharmaceutical manufacturers as of October 27, 2026, the updated maximum retail prices (MRPs) will formally take effect across pharmacies nationwide on November 9, 2026. With some critical chemotherapy regimens and targeted oncology therapies witnessing price cuts exceeding 90 percent, the regulatory mandate offers immediate fiscal relief for households managing high monthly medical bills.

Massive Price Reductions: Critical Therapies Witness Up to 93% Drop

The revised pricing structure introduces steep cuts across multiple high-demand oncology formulations:

• Palbociclib Price Plunge: A 21-capsule pack of 125 mg Palbopro (palbociclib), widely prescribed for targeted advanced breast cancer management, has been slashed from ₹40,421 down to ₹2,720—marking a steep 93% price drop on a single pack.

• Chemotherapy Injections Reduced: Prices have been trimmed for vital chemotherapy agents, including the 100 mg injection of Thiotepa sold under the brand name Samtepa, easing infusion expenses for inpatient oncology treatments.

• Brand-Specific Relief: Reductions vary across formulations, meaning individual patient savings will correspond to the specific molecule, dosage strength, and brand prescribed by treating oncologists.

Capping the Trade Margin: How the Government Brought Down Oncology Prices

The regulatory price correction stems from targeted trade-margin rationalization rather than standard manufacturer-side caps alone:

• Trade Margin Rationalization: Beyond direct manufacturing costs, supply chain layers—including regional stockists, institutional distributors, and retail hospital pharmacies—traditionally added steep markups known as trade margins.

• 30% Cap on Retail Markups: On October 17, the central government capped distributors' trade margins on 137 designated anti-cancer medicines at a maximum of 30 percent of the Maximum Retail Price (MRP).

• Mandatory Data Filing & Enforcement: Following the margin rationalization directive, pharmaceutical enterprises submitted revised calculations, allowing the NPPA to issue the consolidated schedule of 543 products to ensure affordable cancer healthcare.